Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives.

Majcher U, Klejborowska G, Moshari M, Maj E, Wietrzyk J, Bartl F, Tuszynski JA, Huczyński A.

Cells. 2018 Nov 1;7(11). pii: E192. doi: 10.3390/cells7110192.

2.

Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.

Majcher U, Urbaniak A, Maj E, Moshari M, Delgado M, Wietrzyk J, Bartl F, Chambers TC, Tuszynski JA, Huczyński A.

Bioorg Chem. 2018 Dec;81:553-566. doi: 10.1016/j.bioorg.2018.09.004. Epub 2018 Sep 12.

PMID:
30248507
3.

Synthesis, antiproliferative activity and molecular docking of Colchicine derivatives.

Huczyński A, Majcher U, Maj E, Wietrzyk J, Janczak J, Moshari M, Tuszynski JA, Bartl F.

Bioorg Chem. 2016 Feb;64:103-12. doi: 10.1016/j.bioorg.2016.01.002. Epub 2016 Jan 12.

PMID:
26794327
4.

Interactions of long-chain homologues of colchicine with tubulin.

Marzo-Mas A, Barbier P, Breuzard G, Allegro D, Falomir E, Murga J, Carda M, Peyrot V, Marco JA.

Eur J Med Chem. 2017 Jan 27;126:526-535. doi: 10.1016/j.ejmech.2016.11.049. Epub 2016 Nov 23.

PMID:
27915168
5.

Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.

Verdier-Pinard P, Lai JY, Yoo HD, Yu J, Marquez B, Nagle DG, Nambu M, White JD, Falck JR, Gerwick WH, Day BW, Hamel E.

Mol Pharmacol. 1998 Jan;53(1):62-76.

6.

Synthesis, biological evaluation and molecular docking studies of aminochalcone derivatives as potential anticancer agents by targeting tubulin colchicine binding site.

Wang G, Peng Z, Zhang J, Qiu J, Xie Z, Gong Z.

Bioorg Chem. 2018 Aug;78:332-340. doi: 10.1016/j.bioorg.2018.03.028. Epub 2018 Apr 3.

PMID:
29627654
7.

Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues.

do Amaral DN, Cavalcanti BC, Bezerra DP, Ferreira PM, Castro Rde P, Sabino JR, Machado CM, Chammas R, Pessoa C, Sant'Anna CM, Barreiro EJ, Lima LM.

PLoS One. 2014 Mar 10;9(3):e85380. doi: 10.1371/journal.pone.0085380. eCollection 2014.

8.

Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.

Courbet A, Bec N, Constant C, Larroque C, Pugniere M, El Messaoudi S, Zghaib Z, Khier S, Deleuze-Masquefa C, Gattacceca F.

PLoS One. 2017 Aug 10;12(8):e0182022. doi: 10.1371/journal.pone.0182022. eCollection 2017.

9.

Effects on tubulin polymerization and down-regulation of c-Myc, hTERT and VEGF genes by colchicine haloacetyl and haloaroyl derivatives.

Marzo-Mas A, Falomir E, Murga J, Carda M, Marco JA.

Eur J Med Chem. 2018 Apr 25;150:591-600. doi: 10.1016/j.ejmech.2018.03.019. Epub 2018 Mar 8.

PMID:
29550732
10.

Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives.

Tseng CY, Mane JY, Winter P, Johnson L, Huzil T, Izbicka E, Luduena RF, Tuszynski JA.

Mol Cancer. 2010 May 30;9:131. doi: 10.1186/1476-4598-9-131.

11.

Computational design and biological testing of highly cytotoxic colchicine ring A modifications.

Torin Huzil J, Winter P, Johnson L, Weis AL, Bakos T, Banerjee A, Luduena RF, Damaraju S, Tuszynski JA.

Chem Biol Drug Des. 2010 Jun;75(6):541-50. doi: 10.1111/j.1747-0285.2010.00970.x. Epub 2010 Apr 8.

PMID:
20408852
12.
13.

Synthesis, molecular docking and biological evaluation of 1-phenylsulphonyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as novel potential tubulin assembling inhibitors.

Wang YT, Cai XC, Shi TQ, Zhang YL, Wang ZC, Liu CH, Zhu HL.

Chem Biol Drug Des. 2017 Jul;90(1):112-118. doi: 10.1111/cbdd.12932. Epub 2017 Feb 15.

PMID:
28032450
14.

In-silico Investigation of Tubulin Binding Modes of a Series of Novel Antiproliferative Spiroisoxazoline Compounds Using Docking Studies.

Abolhasani H, Zarghi A, Hamzeh-Mivehroud M, Alizadeh AA, Shahbazi Mojarrad J, Dastmalchi S.

Iran J Pharm Res. 2015 Winter;14(1):141-7.

15.

Synthesis, structure-activity relationships and biological evaluation of 7-phenyl-pyrroloquinolinone 3-amide derivatives as potent antimitotic agents.

Carta D, Bortolozzi R, Sturlese M, Salmaso V, Hamel E, Basso G, Calderan L, Quintieri L, Moro S, Viola G, Ferlin MG.

Eur J Med Chem. 2017 Feb 15;127:643-660. doi: 10.1016/j.ejmech.2016.10.026. Epub 2016 Oct 21.

16.

Characterization of the colchicine binding site on avian tubulin isotype betaVI.

Sharma S, Poliks B, Chiauzzi C, Ravindra R, Blanden AR, Bane S.

Biochemistry. 2010 Apr 6;49(13):2932-42. doi: 10.1021/bi100159p.

17.

Synthesis, antiproliferative and antibacterial evaluation of C-ring modified colchicine analogues.

Huczyński A, Rutkowski J, Popiel K, Maj E, Wietrzyk J, Stefańska J, Majcher U, Bartl F.

Eur J Med Chem. 2015 Jan 27;90:296-301. doi: 10.1016/j.ejmech.2014.11.037. Epub 2014 Nov 22.

PMID:
25437616
18.

Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin.

Kim DY, Kim KH, Kim ND, Lee KY, Han CK, Yoon JH, Moon SK, Lee SS, Seong BL.

J Med Chem. 2006 Sep 21;49(19):5664-70.

PMID:
16970393
19.

Design, synthesis and molecular docking of novel diarylcyclohexenone and diarylindazole derivatives as tubulin polymerization inhibitors.

Ahmed RI, Osman EE, Awadallah FM, El-Moghazy SM.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):176-188. doi: 10.1080/14756366.2016.1244532. Epub 2016 Oct 24.

Supplemental Content

Support Center